MREO Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 123274 min ago

@ $3.74

Ausgestellt: 14 Feb 2024 @ 18:33

Rendite: -12.57%

Vorheriges Signal: Feb 14 - 17:06

Vorheriges Signal: Verkaufen

Rendite: 0.00 %

Live Chart Being Loaded With Signals

Commentary (9 Mai 2024 @ 22:00):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
Tagesvolumen	499 463
Durchschnittsvolumen	1.17M
Marktkapitalisierung	457.99M
EPS	$0 ( 2024-03-26 )
Nächstes Ertragsdatum	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.35
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.62
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

Volumen Korrelation

Lang: 0.12 (neutral)

Kurz: -0.21 (neutral)

Signal:(54.729) Neutral

Mereo BioPharma Group plc Korrelation

10 Am meisten positiv korreliert
CFBK	0.888
SLNO	0.887
PBPB	0.885
PROV	0.873
ECOR	0.867
ARDX	0.865
RBKB	0.861
ISTR	0.854
CXDO	0.854
CPLP	0.851

10 Am meisten negativ korreliert
OSMT	-0.878
PFBI	-0.858
HCM	-0.847
MLVF	-0.847
IQ	-0.844
RMRM	-0.843
BFRI	-0.838
COCO	-0.833

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Mereo BioPharma Group plc Korrelation - Währung/Rohstoff

-0.37
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.54
( weak )

0.50
( neutral )

Mereo BioPharma Group plc Finanzdaten

Annual	2023
Umsatz:	$10.00M
Bruttogewinn:	$7.43M (74.26 %)
EPS:	$0

FY	2023
Umsatz:	$10.00M
Bruttogewinn:	$7.43M (74.26 %)
EPS:	$0

FY	2022
Umsatz:	$1.51M
Bruttogewinn:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
Umsatz:	$36.46M
Bruttogewinn:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.